Impact of sodium-glucose cotransporter-2 inhibitors on ovarian cancer risk in patients with type 2 diabetes mellitus: A multi-institutional TriNetX study
Main finding · Ovarian cancerResult — go to the resultHazard ratio 0.758 95 % CI 0.596–0.965Authors' conclusion
Our study suggests that SGLT2i may be associated with lower risk of ovarian cancer in T2DM patients. These findings highlight the need for further investigation into the underlying mechanisms.
Study context
- Population
- Patients with T2D, TriNetX network, January 2013–December 2023Propensity score matching (PSM) cohort
- Participants
- 92,090 vs 92,090
- Exposure
- SGLT2i vs DPP-4i
- SGLT2in = 92,090
- DPP4in = 92,090reference
- Outcome
- Incidence of ovarian cancer
Methodological detailsmulti-institutional, new-user design, active comparator, propensity-score matched
- Multi-institutional
- New-user design
- Active comparator
- Propensity-score matched
Main finding
Ovarian cancer
Hazard ratio
0.758
95 % CI 0.596–0.965
SGLT2ivs DPP4i
HR 0.758 (95 % CI 0.596–0.965)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95 % CI) | |
|---|---|---|
| Ovarian cancer, white patients (subgroup) | 0.667 (0.485–0.917) | |
| 0.512Hazard ratio (log scale) |
Ovarian cancer, white patients (subgroup)
- Subgroup analyses revealed a consistent trend across various populations
Original publication
Impact of sodium-glucose cotransporter-2 inhibitors on ovarian cancer risk in patients with type 2 diabetes mellitus: A multi-institutional TriNetX study. Diabetes Res Clin Pract. Published 18 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →